Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial

• Hang Li,
• Hao Cheng,
• Qianjin Lu,
• Wei Lai,
• Xiaohua Tao,
• Gerardo A. Encinas,
• Shefali Vyas,
• Bo Wang,
• Xin Luo,
• Shiqi Li,
• Lishao Guo

Affiliations

Hang Li

1 Department of Dermatology, Peking University First Hospital, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China

Hao Cheng

2 Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China

Qianjin Lu

3 Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China

Wei Lai

4 Department of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China

Xiaohua Tao

5 Department of Dermatology, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China

Gerardo A. Encinas

6 Pfizer S.A. de C.V., Mexico City, Mexico

Shefali Vyas

7 Pfizer Inc., New York, NY, USA

Bo Wang

8 Pfizer Investment Co., Ltd, Beijing 100010, China

Xin Luo

9 Pfizer (China) R&D Co., Ltd, Shanghai 201200, China

Shiqi Li

10 Pfizer PBG, Shanghai 200041, China

Lishao Guo